
Photo: Ars Technica
Technology
The FDA wants to pull its approval of a drug. It’s not so easy.
TL;DR
- The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Oct 31, 2026 · Updated 10/31/2026, 12:06:06 PM · Reported with: Ars Technica
Sources (1)
NRI Bytes writes its own articles from the reporting below.
Ars Technica — The FDA wants to pull its approval of a drug. It’s not so easy.Up next · Technology
Nvidia’s startup stakes ballooned to $65B, but Huang’s exit puts future deals in doubt
Read next →
More stories
Technology
OpenAI bugging case defendant Alfozan set for trial in January
43m ago

Technology
CAG develops AI tools for audits, projects ready for pan-India launch
59m ago
Technology
Many of Amazon's Black Friday and Cyber Monday deals are often deceptive, think tank says
59m ago
Technology
Apple outage: iPhone maker rules out cyberattack, says most systems restored after internal update caused disruption
1h ago

